Moderna (MRNA) shares are trading higher Monday after the biotechnology company revealed the start of a clinical trial for a skin cancer treatment. Moderna has partnered with the pharmaceutical giant Merck (MRK) to test the drug, in a bid to diversify beyond its core vaccine business.
Yahoo Finance’s Julie Hyman and Brian Sozzi breaks down the details.
For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Editor’s note: This article was written by Angel Smith
